Eli Lilly Tops On Diabetes, Chemo Strength But A Key Drug Lagged [Investor's Business Daily]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Investors Business Daily
Related news 4/23/2018 Merck popped to a three-month high Monday after Goldman Sachs suggested its cancer drug, Keytruda, could be a $16 billion... Premarket Trading: Futures Rise As Merck, CAT Get Upgrades Why Dow Jones' Merck Looks Poised To Edge Out Bristol In Lung Cancer J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs Premarket Trading: Blue Chips, Netflix Power Up; China Adds Tariffs Dow Hits Resistance At 50-Day As Apple Stock Moves Higher Bristol Topples After Merck Treatment Outperforms It In Lung Cancer Tests Can This Smaller Biotech Actually Rival Merck, Bristol In Cancer Drugs? NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure Eli Lilly ( LLY ) topped the Street's first-quarter estimates Tuesday on unexpected strength from two diabetes drugs and the early impact of a chemotherapy tie with Dow Jones' component Merck ( MRK ). But sales of psoriasis drug Taltz, a key growth product, and osteoporosis drug F
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Immutep reports promising efti/Keytruda data for head and neck cancer [Seeking Alpha]Seeking Alpha
- Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday? [Yahoo! Finance]Yahoo! Finance
- Oncology Market Expected to Grow at 9.6% CAGR, Reaching USD 533.2 Bn by 2032 | DMR [Yahoo! Finance]Yahoo! Finance
- Vaccines Market Worth $94.9 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024 [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- MRK's page on the SEC website